Brilliant Violet 421™ anti-mouse CD3 Antibod
- 产品名称：
- Brilliant Violet 421™ anti-mouse CD3 Antibod
- 产品类别：
- 抗体
- 产品编号：
- 100227
- 产品应用：
- 100227
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- γδTCR-positive T-T hybridoma D1
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- ?g sizes: 0.2 mg/mL?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
ICC - Verified
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤ 0.25 ?g per million cells in 100 ?l volume. For immunocytochemistry using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.
- Application References
(PubMed link indicates BioLegend citation) -
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Kalinina A, et al. 2021. STAR Protoc. 2:100368. PubMed
- Sch?dlich IS, et al. 2022. iScience. 25:104470. PubMed
- John S, et al. 2020. Sci Rep. 10:11377. PubMed
- Chukkapalli S, et al. 2015. Pathog Dis. 73:9. PubMed
- Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
- Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
- Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
- Chen J, et al. 2022. Nat Commun. 13:6759. PubMed
- Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
- Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
- Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941. PubMed
- Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
- Royzman D, et al. 2022. Front Immunol. 13:1012647. PubMed
- Bertocchi A, et al. 2021. Cancer Cell. 39(5):708-724.e11. PubMed
- Chao CC, et al. 2020. Cell. 179(7):1483-1498.e22.. PubMed
- Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
- Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
- Trenevska I, et al. 2021. PLoS One. 16:e0249967. PubMed
- Emg?rd J, et al. 2018. Immunity. 143:419. PubMed
- Glaser AK, et al. 2019. Nat Commun. 10:2781. PubMed
- Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
- Cameron G, et al. 2015. J Immunol. 195: 4604 - 4614. PubMed
- Telford W, et al. 2017. Cytometry A. 91:314. PubMed
- Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
- Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
- Solaymani-Mohammadi S, et al. 2016. J Leukoc Biol. 99: 475 - 482. PubMed
- Chukkapalli S, et al. 2015. PLoS One. 10: 0143291. PubMed
- Jin C, et al. 2019. Cell. 176:998. PubMed
- Hasegawa T, et al. 2020. Sci Rep. 10:13480. PubMed
- Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
- Zhu D, et al. 2017. Stem Cell Res Ther. 0.511805556. PubMed
- Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
- Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
- Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
- Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
- Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
- Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
- Tummala G, et al. 2021. Invest Ophthalmol Vis Sci. 62:41. PubMed
- Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
- Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
- RRID
- AB_10900227 (BioLegend Cat. No. 100227) AB_2562553 (BioLegend Cat. No. 100228)
- Structure
- Ig superfamily, CD3/TCR, 20 kD
- Distribution
-
Thymocytes (differentiation dependent), mature T cells, NK-T cells
- Function
- Antigen recognition, TCR signal transduction, T cell activation
- Ligand/Receptor
- Peptide antigen/MHC-complex
- Antigen References
-
1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.
- Gene ID
- 12502 View all products for this Gene ID
- UniProt
- View information about CD3 on UniProt.org
